About this trial
This multi-center retrospective cohort study aims to investigate the real-world outcomes of chronic subdural hematoma treated with MMAE, including clinical effectiveness, recurrence rates, and safety profile.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Consecutive adult patients (18 yrs. of age or older)
Disqualifiers
Endovascular embolization of middle meningeal artery using any other embolization material
Trial population
Patients with chronic subdural hematoma
Trial design
Cohort
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Reaccumulation of Hematoma
The percentage of patients who were determined to have a reaccumulation of their hematoma will be tabulated and reported
Rescue surgical evacuation
The percentage of patients who were determined to require rescue surgical evacuation of their hematoma will be tabulated and reported
Secondary outcomes
Reaccumulation of Hematoma
The percentage of patients who were determined to have a reaccumulation of their hematoma will be tabulated and reported. Reaccumulation of the hematoma will be determined by measuring the hematoma thickness at a given time point and comparing it to the thickness measured at the previous time point.
Reaccumulation of Hematoma
The percentage of patients who were determined to have a reaccumulation of their hematoma will be tabulated and reported. Reaccumulation of the hematoma will be determined by measuring the hematoma thickness at a given time point and comparing it to the thickness measured at the previous time point.
Reaccumulation of Hematoma
The percentage of patients who were determined to have a reaccumulation of their hematoma will be tabulated and reported. Reaccumulation of the hematoma will be determined by measuring the hematoma thickness at a given time point and comparing it to the thickness measured at the previous time point.
Reaccumulation of Hematoma
The percentage of patients who were determined to have a reaccumulation of their hematoma will be tabulated and reported. Reaccumulation of the hematoma will be determined by measuring the hematoma thickness at a given time point and comparing it to the thickness measured at the previous time point.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Montefiore Medical Center
Lead sponsor
Geisinger Clinic
Collaborator
Heidelberg University
Collaborator
Henri Mondor University Hospital
Collaborator
Ospedale Policlinico San Martino
Collaborator
Ospedale San Raffaele
Collaborator
Lehigh Valley Hospital
Collaborator
Mayo Clinic
Collaborator
Medical University of South Carolina
Collaborator
New York University
Collaborator
Oregon Health and Science University
Collaborator
Sisters of Mercy University Hospital
Collaborator
Unity Health Toronto
Collaborator
Sutter Health
Collaborator
University of Iowa
Collaborator
Thomas Jefferson University
Collaborator
University Health Network, Toronto
Collaborator
University Hospital, Bordeaux
Collaborator
University of Alabama at Birmingham
Collaborator
University of South Florida
Collaborator
University of Washington
Collaborator
Cornell University
Collaborator
Westchester Medical Center
Collaborator